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Transcatheter Aortic Valve Replacement
With the St. Jude Medical Portico Valve
First-in-Human Experience
Alexander B. Willson, MBBS, MPH,* Josep Rodès-Cabau, MD,† David A. Wood, MD,*
Jonathon Leipsic, MD,* Anson Cheung, MD,* Stefan Toggweiler, MD,* Ronald K. Binder, MD,*
Melanie Freeman, MBBS,* Robert DeLarochellière, MD,† Robert Moss, MBBS,*
Luis Nombela-Franco, MD,† Eric Dumont, MD,† Karolina Szummer, MD,*
Gregory P. Fontana, MD,‡ Raj Makkar, MD,§ John G. Webb, MD*
Vancouver, British Columbia, and Quebec City, Quebec, Canada; New York, New York;
and Los Angeles, California
Objectives The purpose of this study was to demonstrate the feasibility and procedural outcomes with a new self-expanding
and repositionable transcatheter heart valve.
Background Transcatheter aortic valve replacement is a viable option for selected patients with severe symptomatic aortic
stenosis. However, suboptimal prosthesis positioning may contribute to paravalvular regurgitation, atrioventricu-
lar conduction block, and mitral or coronary compromise.
Methods The repositionable Portico valve (St. Jude Medical, Minneapolis, Minnesota) was implanted in 10 patients with
severe aortic stenosis utilizing percutaneous femoral arterial access. Patients underwent transthoracic and
transesophageal echocardiography and multidetector computed tomography before and after valve implanta-
tion. Clinical and echocardiographic follow-up was obtained at 30 days.
Results Device implantation was successful in all patients. Prosthesis recapture and repositioning was performed in
4 patients. Intermittent prosthetic leaflet dysfunction in 1 patient required implantation of a second transcathe-
ter valve. There was 1 minor stroke. At 30-day follow-up, echocardiographic mean transaortic gradient was re-
duced from 44.9  16.7 mm Hg to 10.9  3.8 mm Hg (p  0.001), and valve area increased from 0.6  0.1
cm2 to 1.3  0.2 cm2 (p  0.001). Paravalvular regurgitation was mild or less in 9 patients (90%) and moder-
ate in 1 patient (10%). There were no major strokes, major vascular complications, major bleeds, or deaths.
No patient required pacemaker implantation. All patients were in New York Heart Association functional
class II or less.
Conclusions Transcatheter aortic valve replacement with the repositionable Portico transcatheter heart valve is feasible, with
good short-term clinical and hemodynamic outcomes. (J Am Coll Cardiol 2012;60:581–6) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.045New transcatheter heart valves (THV) may attempt to
improve on the limitations of current systems. Potentially
desirable enhancements may reduce vascular injury, improve
the ease and accuracy of positioning and deployment, or
improve paravalvular sealing. The ability to reposition,
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THV may be particularly desirable when the initial implant
positioning is suboptimal. We describe the first-in-human
experience with the self-expanding repositionable Portico
THV (St. Jude Medical, Minneapolis, Minnesota).
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Patients. Transcatheter aortic
valve replacement (TAVR) was
performed in 10 high-risk patients
with severe symptomatic aortic
stenosis at 2 centers (St. Paul’s
Hospital, Vancouver, British Co-
lumbia, and the Quebec Heart and
Lung Institute, Quebec City,
Quebec) between June and Sep-
tember 2011. All patients gave in-
formed, written consent. Inclusion
criteria are documented in Table 1.
Valve and delivery system. The
trileaflet Portico THV consists
of a nitinol self-expanding frame, bovine pericardial leaflets,
and a porcine pericardial sealing cuff (Fig. 1). The outflow
portion of the stent frame incorporates 3 retention tabs,
which secure the crimped valve to the delivery system. The
Portico valve is sized according to the nominal external stent
diameter at the valvular level. Currently, only the 23-mm
device is available.
The catheter consists of a soft tapered nose cone, an 18F
capsule that contains the compressed valve, and a 12F shaft.
A handle incorporates mechanisms to unsheath and release
the valve using a rotating thumbwheel.
Procedures. All procedures were performed under general
anesthesia with transesophageal echocardiography (TEE). The
common femoral artery was punctured (1), and an 18F
Ultimum sheath (St. Jude Medical) or Drysheath (Gore
Medical, Newark, Delaware). Rapid ventricular pacing was not
utilized during THV deployment. The delivery catheter was
advanced over a guidewire (Amplatz Extra-Stiff 0.0035 inch,
Cook Medical, Bloomington, Indiana) into the left ventricle
(Fig. 2). By rotating the thumbwheel, the inflow of the THV
was unsheathed until slightly flared. The THV was then
withdrawn to approximately 5 mm to 8 mm below the basal
insertion of the native leaflets, as determined by angiography.
By further rotating the thumbwheel, the annular portion of the
THV was fully deployed. At this time, the valve leaflets will be
fully functional, and the retention tabs remain secure within
the capsule (Online Videos 1 and 2).
The position of the functioning THV was then assessed by
TEE and aortography. If not satisfactory, then THV reposi-
tioning could be accomplished by traction on the delivery
catheter. Alternatively, and preferably, rotating the
thumbwheel in a reverse direction allows the THV to be
partially or completely recaptured, enabling the THV to
be redeployed or removed. When a satisfactory position was
achieved, the thumbwheel was fully rotated to release the THV.
The access site was closed percutaneously (ProGlide,
Abbott, Abbott Park, Illinois). The transvenous pacing
ire was generally removed at the completion of the
rocedure. Patients were monitored for at least 48 h
Abbreviations
and Acronyms
LVEF  left ventricular
ejection fraction
MDCT  multidetector
computed tomography
TAVR  transcatheter
aortic valve replacement
TEE  transesophageal
echocardiography
THV  transcatheter heart
valve
TTE  transthoracic
echocardiographyefore discharge. Se
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August 14, 2012:581–6 The Portico ValveImaging. Screening included transthoracic echocardiogra-
phy (TTE), and coronary, aortic root, and descending
angiography, as well as cardiac, aortic, and iliofemoral
multidetector computed tomography (MDCT) angiogra-
phy. The TEE and aortic root angiography were performed
before and after implantation. The TTE was repeated
before hospital discharge and at 1 month (2).
38 mm 
47 mm 
23 mm 
21 mm 
12 french 18 french 
Figure 1 Portico Transcatheter Heart Valve
The 23-mm trileaflet Portico transcatheter heart valve consists of a nitinol
self-expandable stent and bovine pericardial leaflets, with an 18-F delivery
catheter.
A B 
D E 
Figure 2 Delivery and Deployment of Portico THV
(A) The fully sheathed transcatheter heart valve (THV). (B) Transversing the aortic
tional during positioning. (E) Recapture is possible if required. (F) Post-deploymenDepth of implant from the base of the coronary cusps to
the inflow of the THV was measured on post-implant
angiography (3). The THV dimensions at the inflow,
valvular, and outflow level were measured by post-implant
MDCT (Fig. 4) (4–6). A circular THV was defined by an
eccentricity score 10% (eccentricity  1 minus minimum
external stent diameter divided by maximum external stent
diameter) (4,6). The THV expansion was calculated as
external THV area divided by nominal external THV area,
where 100% represents a fully expanded valve (4). Nominal
external THV area is 4.15 cm2 at the inflow and valvular
evel and 11.3 cm2 at the outflow.
Statistical analysis. Continuous variables are described as
mean  SD or medians with interquartile range. Categor-
cal variables are described by frequencies and percentages.
ontinuous parametric variables were compared using the
aired Student t test. All p values 0.05 were considered
ignificant. Valve Academic Research Consortium reporting
uidelines were utilized (7).
esults
aseline characteristics. Clinical characteristics are listed
n Table 2. Pre-procedural MDCT was performed in 7
atients (3 had renal dysfunction). The MDCT-derived
ean annular diameter was 20.6  1.7 mm, and MDCT
nnular area was 3.5  0.5 cm2.
Outcomes. Prosthetic valve delivery, deployment, removal
of the delivery system, and percutaneous vascular closure
were successful in all cases. Initial positioning of the
C 
F 
(C) The THV is flared in the left ventricular outflow tract. (D) The THV is func-
ography demonstrates a competent valve and patent left coronary artery.arch.
t angi
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The Portico Valve August 14, 2012:581–6expanded valve was suboptimal in 4 patients. In all cases,
recapture and repositioning of the valve was easily accom-
plished without withdrawing the system out of the aortic
root.
At 30-day follow-up, there were no deaths, myocardial
infarctions, major or minor bleeds, or major vascular com-
plications (Table 3). One patient had a minor stroke
B A 
Figure 3 Intermittent Transvalvular Regurgitation
(A) Normal leaflet closure. (B) Mild paravalvular leak. (C) Incomplete closure of a
(D) Transvalvular regurgitation. A second transcatheter heart valve was implanted
1
2
A 3
C
C
D
Figure 4 Portico Stent Eccentricity
(A) Stent eccentricity was assessed by multidetector computed tomography (MDC
tion of the Portico valve. As demonstrated in 1 case, the stent eccentricity varied from t(modified Rankin score 1) (8). There was 1 minor vascular
complication (hematoma).
New left bundle branch block developed in 2 patients.
None of 9 patients without a pre-existing pacemaker re-
quired insertion of a permanent pacemaker. The mean
depth of implant was 6.4 1.0 mm below the non-coronary
cusp and 7.0  1.5 mm below the left coronary cusp.
 D 
leaflet (arrow) adjacent to the site of paravalvular regurgitation.
solution of the paravalvular leak and normal valve function.
E
he inflow, valvular, and outflow stent levels. (B) MDCT 3-dimensional reconstruc-C
single
with re 
 
 B
T) at t
he (C) inflow level, 13.6%, (D) valvular level, 5.7%, and (E) outflow level, 0%.
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August 14, 2012:581–6 The Portico ValveTransaortic gradient decreased from 44.9 16.7 mm Hg
to 10.7  4.5 mm Hg (p  0.001), and aortic valve area
ncreased from 0.6  0.1 cm2 to 1.4  0.2 cm2 (p  0.001)
Table 4). Paravalvular regurgitation as assessed by TTE at
ospital discharge was trivial or less in 4 (40%), mild in 5
50%), and moderate in 1 (10%).
One patient with a calcified eccentric annulus (18.4 
4.4 mm by MDCT) and a small hypermobile calcific
alvular nodule had severe transvalvular regurgitation after
ortico implantation and release. There was a moderate
aravalvular leak, and the THV appeared to be positioned
lightly low. Consequently, 1 of the 3 retention tabs was
nared (Gooseneck, AGA Medical, Minneapolis, Minne-
ota), and the THV was pulled a few millimeters higher.
aravalvular regurgitation was reduced to mild, and trans-
alvular regurgitation disappeared. Post-procedure severe
ransvalvular regurgitation recurred intermittently. The
EE suggested that was due to intermittent failure of a
ingle, otherwise normal leaflet adjacent to the paravalvular
eak (Fig. 3). A second 23-mm Portico THV was implanted
ithin the first valve (THV-in-THV) 7 days later. There
as complete resolution of the valvular insufficiency with
esidual trivial paravalvular insufficiency, a mean gradient of
4 mm Hg, and valve area of 1.4 cm2.
Follow-up. At 30 days all patients remained alive. New
York Heart Association functional class was I in 6
patients (75%) and class II in 4 patients (25%). The
30-day echocardiography documented a mean transaortic
Baseline Characteristics (N  10)Table 2 Baseline Characteristics (N  10)
Age, yrs 82.4 5.7
Female 10 (100%)
Diabetes mellitus 5 (50%)
Height, m 1.58 0.09
Weight, kg 58.0 (50.5, 67.1)
Prior CABG 1 (10%)
Prior pacemaker 1 (10%)
COPD 2 (20%)
Frailty 7 (70%)
Porcelain aorta 1 (10%)
STS PROM, % 8.1 3.2
NYHA functional class pre-TAVR
I 0 (0%)
II 2 (20%)
III 8 (80%)
IV 0 (0%)
Glomerular filtration rate, ml/min 47.1 18.8
Mean TEE aortic annulus diameter, mm 19.4 1.6
Mean AVA, cm2 0.62 0.15
Mean transaortic gradient, mm Hg 44.5 17.5
LVEF, % 57.3 13.8
Moderate or severe mitral regurgitation 5 (50%)
Values are mean  SD, median (25th to 75th percentile), or n (%).
AVA  aortic valve area, CABG  coronary artery bypass surgery, COPD  chronic obstructive
pulmonary disease; LVEF  left ventricular ejection fraction; TEE  transesophageal echocardiog-
raphy; STS PROM Society of Thoracic Surgeons predicted risk of mortality; TAVR transcatheter
aortic valve replacement.gradient of 10.9  3.8 mm Hg (p  0.001) and meanaortic valve area of 1.3  0.2 cm2 (p  0.001). All
patients were discharged from hospital, and no patient
required rehospitalization. Paravalvular regurgitation was
none or trace in 5 patients (50%), mild in 4 (40%), and
moderate in 1 patient (10%). No patient had more than
trivial transvalvular regurgitation.
THV expansion. All patients underwent post-implantation
MDCT before hospital discharge (Fig. 4). Aortic annular
eccentricity pre-TAVR was greater than inflow THV ec-
centricity (20.1  6.2% vs. 12.8  6.1%, p  0.01). The
THV eccentricity was maximal at the inflow (12.8  6.1%)
and valvular level (12.0  7.3%), and least at the outflow
(2.4  1.2%). The THV with intermittent leaflet dysfunc-
tion was 18% eccentric at the valvular level. Circularity was
seen in 4 valves at the inflow and valvular level and 10 at the
outflow level. Mean THV expansion was 88.2  16.6% at
the inflow, 88.1  10.5% at the valvular level, and 65.0 
9.1% at the outflow.
Discussion
We document the first-in-human experience with the
Portico self-expanding transcatheter aortic bioprosthesis.
The Portico THV was delivered and deployed success-
fully in all patients. There were no major periprocedural
complications. All patients in this high-risk cohort re-
mained alive at 30 days with a marked improvement in
functional class.
Recapture and positioning. A desirable feature is the po-
tential to be deployed to the point of functionality while
allowing for controlled recapture, followed either by reposi-
tioning and redeployment or by removal. Recapture and
repositioning was successfully accomplished in 4 patients. The
ability to reposition the valve may be helpful in reducing the
likelihood of problematic paravalvular regurgitation, coronary
obstruction, mitral interference, and atrioventricular block.
Atrioventricular block. Although numbers were small, the
absence of high-grade block requiring pacemaker implan-
tation is reassuring. In comparison, the rates of pacemaker
implantation due to new conduction block have been high
with the self-expandable CoreValve device (Medtronic,
Minneapolis, Minnesota), likely as a consequence of septal
30-Day Outcome for the 23-mm Portico ValveTable 3 30-Day Outcome for the 23-mm Portico Valve
Death 0 (0%)
Myocardial infarction 0 (0%)
Major stroke 0 (0%)
Minor stroke 1 (10%)
Major vascular complication 0 (0%)
Minor vascular complication 1 (10%)
Acute kidney injury, modified RIFLE criteria stage 3 0 (0%)
Repeat procedure for valve-related dysfunction 1 (10%)
Permanent pacemaker implantation 0 (0%)
Readmission to hospital 0 (0%)Values are n (%).
RIFLE  risk, injury, failure, loss, end-stage kidney disease.
gurgita
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The Portico Valve August 14, 2012:581–6compression. Contrasting the 2 devices, the Portico valve
does not have a flared inflow (Fig. 1), and the ability to
reposition may facilitate higher implantation. Notably, the
implant depth was less than has been generally reported
with the CoreValve device (3).
Valve function. The mean transaortic gradient of 10.9 mm
Hg is comparable to that of other aortic THVs. The mean
estimated orifice area of 1.3 cm2 is smaller than generally
reported; however, the 23-mm nominal valve size was
intended for patients with small annulus diameter of 18 mm
to 21 mm. By way of comparison, the 23-mm SAPIEN/
SAPIEN XT valve (Edwards Lifesciences, Irvine, Califor-
nia) implanted into patients with small annuli 20 mm by
TEE had a mean orifice area of 1.4 cm2 (8).
Prosthetic valve dysfunction was observed in a single
case. The mechanism remains conjectural. In vitro mod-
eling has demonstrated that a highly eccentric stent frame
in combination with a paravalvular leak can result in an
intermittent “frozen leaflet,” possibly due to equalization
of pressures on either side of the leaflet when fully open.
Although speculative, it is possible that more aggressive
balloon before or after dilation might have resolved this
problem. It is reassuring that implantation of a second
THV was easily accomplished and that hemodynamic
function after THV-in-THV implantation was excellent.
Expansion and eccentricity. Adequate oversizing enables
sufficient radial force to secure the THV, ensure effective
sealing, and minimize paravalvular regurgitation. Some
degree of underexpansion at the inflow level is expected
with self-expandable prostheses. The completeness of
THV expansion and residual eccentricity of the Portico
appeared similar to that of the self-expandable CoreValve
device (6).
Conclusions
The Portico transcatheter heart valve is a new bioprosthesis
Hemodynamic Function After Implantation and at 30-Day Follow-UpTable 4 Hemodynamic Function After Implantation and at 30-D
Pre-TAVR Post-TAVR
Case #
AVA,
cm2
MG,
mm Hg
LVEF,
%
AVA,
cm2 m
1 0.5 59 65 1.0
2 0.5 28 30 1.8
3 0.7 35 70 1.5
4 0.6 38 35 1.4
5 0.8 39 60 1.5
6 0.4 56 58 1.3
7 0.6 40 60 1.1
8 0.6 45 60 1.3
9 0.5 82 70 1.4
10 0.8 27 69 1.4
Mean  SD 0.6 0.1 44.9 16.7 54.7 14.3 1.4 0.2 10.7
MG  mean transaortic gradient; PAR  paravalvular regurgitation; TAR  transvalvular aortic rewith novel repositioning capabilities. Although this is asmall series and follow-up remains limited, the clinical and
echocardiographic outcomes are encouraging. Further eval-
uation is warranted.
Reprint requests and correspondence: Dr. John Webb, St. Paul’s
Hospital, 1081 Burrard Street, Vancouver, British Columbia V6Z
1Y6, Canada. E-mail: john.webb@vch.ca.
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APPENDIX
llow-Up
ospital Discharge 1-Month Post-TAVR
PAR TAR
AVA,
cm2
MG,
mm Hg PAR TAR
Mild None 1.0 15 Mild None
Moderate Trivial 1.6 4 Moderate Trivial
Trivial None 1.5 10 Trivial None
Mild Severe 1.4 14 Trivial None
Trivial None 1.3 8 Trivial None
Trivial None 1.2 10 Trivial None
Mild None 1.1 11 Mild None
Trivial None 1.2 15 Trivial None
Mild None 1.6 7 Mild None
Mild None 1.3 10 Mild None
1.3 0.2 10.9 3.8
tion; TAVR  transcatheter aortic valve replacement; other abbreviations as in Table 2.ay Fo
, Pre-H
MG,
m Hg
14
4
6
13
8
10
16
10
18
8
 4.5For the supplemental videos, please see the online version of this article.
